Chloroma of the Bladder: A Case Report of Leukemia Progression Presenting as Hematuria
We describe a rare case of a 70-year-old man presenting with MS of the urinary bladder complicating known secondary AML (RUNX1 and IDH2 mutated). Prior to development of bladder MS, the patient had received decitabine, enasidenib, and venetoclax. Following diagnosis, he was treated with cytarabine and venetoclax. To our knowledge, this is the first case of bladder MS treated with a BCL-2 inhibitor.Case Rep Oncol 2021;14:1366 –1372
ConclusionOrbital myeloid sarcoma usually exhibits clinical and radiological features that can be easily misleading, especially if it happensde novo or as the first manifestation of acute myeloid leukemia. Only a few isolated cases have reported and proposed trauma as a trigger event of the onset of this type of tumor proliferation, but further investigations and evidence are needed to support this hypothesis.
Intern Med. 2021 Oct 5. doi: 10.2169/internalmedicine.7986-21. Online ahead of print.ABSTRACTMyeloid sarcoma (MS) is a relatively rare manifestation of myeloid neoplasms at sites other than the bone marrow. The rarity of gastrointestinal (GI) MS is attributed to certain factors, such as misdetection due to insufficient endoscopic assessments at the initial presentation with acute myeloid leukemia (AML) as well as the difficulty of making a histologic assessment of leukemic involvement of the GI tract. We herein report a case of AML with gastric involvement and discuss the importance of screening examinations and therapies ...
Myeloid sarcoma (MS) is a tumor secondary to myeloid leukemia that consists of immature granulocytes with or without mature granulocytes and is a rare extramedullary manifestation of acute myeloid leukemia (AML).
We report a case of acute myeloid leukemia with central nervous system-MS presenting as a posterior fossa mass mimicking a primary intracranial tumor.
Eva Lion Despite the advent of novel therapies, acute myeloid leukemia (AML) remains associated with a grim prognosis. This is exemplified by 5-year overall survival rates not exceeding 30%. Even with frontline high-intensity chemotherapy regimens and allogeneic hematopoietic stem cell transplantation, the majority of patients with AML will relapse. For these patients, treatment options are few, and novel therapies are urgently needed. Adoptive T-cell therapies represent an attractive therapeutic avenue due to the intrinsic ability of T lymphocytes to recognize tumor cells with high specificity and efficiency. In par...
We report a case of a 43-year-old man who presented with dyspnea because of large bilateral pleural effusions and imaging findings of a large periaortic mass with compression of the esophagus and left atrium. Subsequent soft tissue biopsy was consistent with myeloid sarcoma, and bone marrow biopsy was consistent with acute myeloid leukemia. He was started on induction and subsequent consolidation chemotherapy with complete remission and shrinkage of the tumor.PMID:34456490 | PMC:PMC8366947 | DOI:10.1080/08998280.2021.1930845